baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Lonza Group AG/ CH0013841017 /

5/31/2024 9:54:37 PM	Chg. +3.0890	Volume	Bid-	Ask-	Market Capitalization	Dividend Y.	P/E Ratio
551.6500USD	+0.56%	85 Turnover: 3,737.3500	-Bid Size: -	-Ask Size: -	40.08 bill.USD	-	-

GlobeNewswire 4/4 Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’...

GlobeNewswire 10/16/2023 Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumoc...

GlobeNewswire 9/7/2023 Institutional Investor Launches 2023 Developed Europe & Emerging Emea Executive Team Rankings

GlobeNewswire 11/2/2021 Lonza to Acquire Codiak BioSciences Exosomes Manufacturing Facility and Establish a Long-Term Strate...

GlobeNewswire 9/8/2021 Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment o...

GlobeNewswire 4/14/2021 aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810

GlobeNewswire 3/12/2021 Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza

GlobeNewswire 1/12/2021 Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the...

GlobeNewswire 1/8/2021 Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager

GlobeNewswire 12/23/2020 Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal

GlobeNewswire 11/10/2020 Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID™ its Single-Dose Intranasal V...

GlobeNewswire 9/4/2020 Institutional Investor Research Publishes 2020 Europe Executive Team Rankings

GlobeNewswire 2/6/2020 Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic...

GlobeNewswire 2/4/2020 Amarantus Releases Letter to Shareholders

GlobeNewswire 1/30/2020 Amarantus Acquires Majority Interest in CBD Wellness Company Hempori

GlobeNewswire 1/2/2020 Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products

GlobeNewswire 12/9/2019 Amarantus to Present at 12th Annual LD Micro Main Event

GlobeNewswire 12/4/2019 Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined w...

GlobeNewswire 11/21/2019 Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorder...

GlobeNewswire 11/18/2019 Amarantus Provides Recapitalization Update to Shareholders

GlobeNewswire 11/14/2019 Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test...

GlobeNewswire 10/30/2019 Global Primary Cells Market Analysis, Trends, and Forecasts Report 2019

GlobeNewswire 10/29/2019 Worldwide Cell Based Assay & High Content Screening Market Forecasts to 2024 - Candidate Growth, Imm...

GlobeNewswire 10/24/2019 Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Org...

GlobeNewswire 10/17/2019 Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblast’s Potential First U...

Lonza Group AG/ CH0013841017 /

If you wish to receive reply to your feedback, please provide your email address.